Max India Limited (MAXIND) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Max India Limited ₹22.75, price ₹163, upside -86.0%, quality 36 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Max India Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ₹67.85 – ₹329.60 · fair‑value band ₹15.01 – ₹28.43 · the ₹162.78 price screens above the ₹22.75 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Max India in your weekly email
Every Wednesday you see whether Max India is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Max India Limited provides services related to senior living communities in India. It operates through four segments: Business Investments, Senior Living, Assisted Care, and Others. The company engages in the treasury investments and investment property businesses. It also offers senior living services.
Show more
Max India Limited provides services related to senior living communities in India. It operates through four segments: Business Investments, Senior Living, Assisted Care, and Others. The company engages in the treasury investments and investment property businesses. It also offers senior living services. In addition, the company caters to the seniors by providing care at home services and care homes facilities, as well as offers Antara AGEasy, which is a new-age holistic direct to consumer platform that helps seniors manage common chronic conditions. Further, it offers daily living/specialized care/memory care services for seniors; and management and consultancy and shared services, as well as MedCare products. Additionally, the company engages in the learning and development activities; construction and leasing of senior living communities; and management of investments activities. The company was formerly known as Advaita Allied Health Services Limited. Max India Limited was incorporated in 2019 and is based in Gurugram, India.
Stock analysis
Max India Limited (MAXIND) currently trades at ₹162.78, while our model-based Fair Value estimate is ₹22.75, 86.0% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: ₹15.01 (bear) to ₹28.43 (bull), the price of ₹162.78 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Max India Limited reported revenue of ₹1.9B in FY2026 versus ₹1.7B in FY2022, a compound +3.0%/yr. Reported net income was −₹1.2B in FY2026.
Key figures
Market cap ₹8.3B (≈ $86.4M) · P/S ratio 3.91 · EPS (TTM) ₹−23.85 · Net margin −63.9% · Return on equity −31.8% · Return on assets (EBIT) −9.3% · Operating margin 0.5% · Revenue (TTM) ₹2.1B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (medium confidence).
What moves the price
The share trades about 26% below its 52-week high and 33% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −86%, MAXIND screens richer than that median.
Fair Value models
Bear ₹15.01Fair Value ₹22.75Bull ₹28.43
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.28/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+31.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.5%
Start year 2021 (pandemic). Over 10 years: −15.1% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.1%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−32.2% (2021) → −68.7% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 246 stocks
Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score36 · Bottom 25%
Fair Value upside−86.0% · Bottom 25%
Profitability
Return on assets−8.7% · Bottom 25%
Net margin (TTM)−57.1% · Bottom 25%
Operating margin (TTM)0.5% · Bottom 25%
Growth and dividend
Revenue growth67.4% · Top 25%
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/S (TTM)0.04× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 34
FUTURE (revenue growth)100· sector 26
PAST (return on equity)0· sector 31
HEALTH (low debt)100· sector 90
DIVIDEND (yield)0· sector 39
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Max India Limited Fair Value". https://www.fairvalue-calculator.com/stock/MAXIND
Frequently asked questions
Is Max India Limited (MAXIND) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ₹22.75 versus a price of ₹162.78, about −86% upside (overvalued).
What is the fair value of MAXIND?
Our model-based fair value for Max India Limited is ₹22.75 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹162.78.
What is the quality score of MAXIND?
Max India Limited has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Max India Limited (MAXIND)?
Our model-based price target is the fair value of ₹22.75 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario ₹15.01, optimistic scenario ₹28.43. It is a calculation from audited fundamentals, not an analyst target.
What is the Max India Limited stock forecast for 2026?
Our models put fair value at ₹22.75, about −86% upside versus a price of ₹162.78 (overvalued). Cautious scenario ₹15.01, optimistic scenario ₹28.43. The calculation is refreshed regularly with new filings.
What is the revenue of Max India Limited (MAXIND)?
Max India Limited reported trailing-twelve-month revenue of about ₹2.1B (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Max India Limited (MAXIND)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Max India Limited it is ₹22.75 per share (as of Sep 24, 2026), against a price of ₹162.78. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Max India Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, MAXIND trades above its calculated fair value: price ₹162.78, fair value ₹22.75, a gap of about −86% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MAXIND?
No. The price is what the market pays today (₹162.78); the fair value is what the company's own numbers justify (₹22.75). For Max India Limited the two are ₹140.03 per share apart. That gap is exactly why we show both numbers side by side.
How much is Max India Limited worth?
The market values Max India Limited at about ₹8.3B (market capitalisation, as of Sep 24, 2026). Per share that is ₹162.78; our models calculate a fair value of ₹22.75 per share.
What do the bullish and bearish scenarios say about MAXIND?
Our models span a range for Max India Limited: cautious scenario ₹15.01, base ₹22.75, optimistic ₹28.43 per share (as of Sep 24, 2026, price ₹162.78). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Max India Limited (MAXIND)?
Balance-sheet figures for Max India Limited (as of Sep 24, 2026): return on equity −31.8%, debt of 0.00 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is MAXIND from its 52-week high?
Max India Limited trades at ₹162.78, about 26% below its 52-week high of ₹218.82 and 33% above the low of ₹122.85 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹22.75 is for.
Which stocks are comparable to Max India Limited?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Max India Limited stock attractive at the current price?
The data as of Sep 24, 2026: price ₹162.78, calculated fair value ₹22.75 (−86%), Quality Score 36/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MAXIND calculated?
We run Max India Limited through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹22.75, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Max India Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Max India Limited (MAXIND)?
The closing price on Oct 1, 2026 was ₹162.78. Our model-based fair value is ₹22.75, about −86% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Max India Limited right now?
The price sits above even our optimistic bull case (₹28.43). The favourable scenario is already priced in. Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (₹15.01 to ₹28.43) leaves room in how you read the outcome.
Key figures of Max India Limited
How large is the market capitalisation of Max India Limited (MAXIND)?
The market capitalisation of Max India Limited is ₹8.3B (≈ $86.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Max India Limited (MAXIND)?
The price-to-sales ratio of Max India Limited is 3.91 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Max India Limited (MAXIND)?
Earnings per share at Max India Limited are ₹−23.85. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Max India Limited (MAXIND)?
The net margin of Max India Limited is −63.9% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Max India Limited (MAXIND)?
The return on equity (ROE) of Max India Limited is −31.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Max India Limited (MAXIND)?
On an EBIT basis the return on assets of Max India Limited is −9.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Max India Limited (MAXIND)?
The operating margin of Max India Limited is 0.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Max India Limited (MAXIND)?
Revenue at Max India Limited is growing +67.4% versus a year earlier (3y avg −3.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Max India Limited (MAXIND) generate?
The free cash flow of Max India Limited is −₹1.4B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Max India Limited (MAXIND) carry?
The net debt of Max India Limited is ₹191M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Max India Limited in the live analysis
One click puts Max India Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
